Cargando…

The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients

Letermovir is the first approved drug for cytomegalovirus (CMV) infection prophylaxis in adult patients who are CMV positive undergoing allogeneic hematopoietic cell transplantation (allo-HCT). Because CMV infection risk varies from patient to patient, we evaluated whether a risk-based strategy coul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sourisseau, Mathilde, Faure, Emmanuel, Béhal, Hélène, Chauvet, Paul, Srour, Micha, Capes, Antoine, Coiteux, Valérie, Magro, Léonardo, Alfandari, Serge, Alidjinou, Enagnon Kazali, Simon, Nicolas, Vuotto, Fanny, Karam, Micheline, Faure, Karine, Yakoub-Agha, Ibrahim, Beauvais, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Transplantation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986711/ https://www.ncbi.nlm.nih.gov/pubmed/36350752 http://dx.doi.org/10.1182/bloodadvances.2022008667

Ejemplares similares

P1324: A RISK-BASED STRATEGY FOR THE USE OF LETERMOVIR IN CMV-POSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
por: Beauvais, D., et al.
Publicado: (2022)

Sensitivity of SARS-CoV-2 variant Delta to serum neutralization in BNT162b2 vaccinees and unvaccinated COVID-19 recovered cases
por: Alidjinou, Enagnon Kazali, et al.
Publicado: (2021)

Evaluation of a rapid semiquantitative lateral flow assay for the prediction of serum neutralizing activity against SARS-CoV-2 variants
por: Hirabidian, Mickael, et al.
Publicado: (2022)

2121. The Impact of Donor CMV Serostatus on Outcomes of CMV Infections in the Era of Letermovir
por: Aramburo, Oscar Morado, et al.
Publicado: (2022)

1897. Letermovir Salvage for Complicated Cases of Resistant CMV
por: Turner, Nicholas, et al.
Publicado: (2018)

Respiratory virus detection in returning travelers and pilgrims from the Middle East
por: Mercier, Ambroise, et al.
Publicado: (2023)

Suppression of CMV Infection with Letermovir in a Kidney Transplant Patient
por: Koepf, Uta S, et al.
Publicado: (2020)

Persistent coxsackievirus B infection and pathogenesis of type 1 diabetes mellitus
por: Nekoua, Magloire Pandoua, et al.
Publicado: (2022)

Impact of CMV reactivation on relapse of acute myeloid leukemia after HCT is dependent on disease stage and ATG
por: Turki, Amin T., et al.
Publicado: (2021)

CMV reactivation after allogeneic HCT is associated with a reduced risk of relapse in acute lymphoblastic leukemia
por: Akahoshi, Yu, et al.
Publicado: (2023)

Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation
por: Ueda Oshima, Masumi, et al.
Publicado: (2023)

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020)

Emergence of human CMV-induced NKG2C(+) NK cells is associated with CD8(+) T-cell recovery after allogeneic HCT
por: van der Ploeg, Kattria, et al.
Publicado: (2023)

Necessity to critically review the automatic results of the Xpert Flu assay
por: Engelmann, Ilka, et al.
Publicado: (2017)

Coxsackievirus B4 Can Infect Human Peripheral Blood-Derived Macrophages
por: Alidjinou, Enagnon Kazali, et al.
Publicado: (2015)

Prospective Evaluation of a Commercial Dengue NS1 Antigen Rapid Diagnostic Test in New Caledonia
por: Alidjinou, Enagnon Kazali, et al.
Publicado: (2022)

A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)
por: Maertens, Johan, et al.
Publicado: (2017)

CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
por: Chavaz, Lara, et al.
Publicado: (2023)

Emergence of Q493R mutation in SARS-CoV-2 spike protein during bamlanivimab/etesevimab treatment and resistance to viral clearance
por: Guigon, Aurélie, et al.
Publicado: (2022)

Emergence of Fluoxetine-Resistant Variants during Treatment of Human Pancreatic Cell Cultures Persistently Infected with Coxsackievirus B4
por: Alidjinou, Enagnon Kazali, et al.
Publicado: (2019)

580. Refractory and Resistant CMV Infections in Hematopoietic Cell Transplant Recipients in the Letermovir Primary Prophylaxis Era
por: Sassine, Joseph, et al.
Publicado: (2020)

Combined Therapy with Intravenous Immunoglobulins, Letermovir and (Val-)Ganciclovir in Complicated Courses of CMV-Infection in Transplant Recipients
por: Di Cristanziano, Veronica, et al.
Publicado: (2021)

922. The Impact of Clinically Significant CMV Infections on Other Viral Infections in the Era of Letermovir Primary Prophylaxis
por: Spallone, Amy, et al.
Publicado: (2021)

Fighting Enteroviral Infections to Prevent Type 1 Diabetes
por: Nekoua, Magloire Pandoua, et al.
Publicado: (2022)

Four complete genomes of human parvovirus B19 from amniotic fluid specimens
por: Alidjinou, Enagnon Kazali, et al.
Publicado: (2023)

2296. Development of a Sequencing-Based Assay for Detection of CMV Antiviral Resistance Mutations to Letermovir in UL56
por: Grantham, James, et al.
Publicado: (2018)

1102. Reconstitution of CMV-specific cell-mediated immunity during letermovir prophylaxis in hematopoietic stem cell recipients
por: Abidi, Maheen, et al.
Publicado: (2020)

Enteroviral Pathogenesis of Type 1 Diabetes: The Role of Natural Killer Cells
por: Nekoua, Magloire Pandoua, et al.
Publicado: (2020)

926. Risk factors for post-letermovir cytomegalovirus (CMV) reactivation in allogeneic hematopoietic stem cell transplant (HSCT) recipients
por: Mendoza, Maria Alejandra, et al.
Publicado: (2023)

Letermovir for cytomegalovirus prophylaxis
Publicado: (2019)

SARS-CoV-2 infection long time after full vaccination is related to a lack of neutralizing antibodies
por: Alidjinou, Enagnon Kazali, et al.
Publicado: (2022)

Rapid syndromic testing for respiratory viral infections in children attending the emergency department during COVID-19 pandemic in Lille, France, 2021–2022
por: Ouafi, Mahdi, et al.
Publicado: (2022)

Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People
por: Demaret, Julie, et al.
Publicado: (2021)

2122. The Impact of HHV-6 DNAemia on hematopoietic cell transplant (HCT) recipients at high risk for CMV reactivation in the era of Letermovir
por: Srinivasan, Krithia, et al.
Publicado: (2022)

Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia
por: Maucher, Marius, et al.
Publicado: (2021)

Fluoxetine Can Inhibit SARS-CoV-2 In Vitro
por: Dechaumes, Arthur, et al.
Publicado: (2021)

Low Serum Levels of Interferon Alpha in COVID-19 Patients Are Associated with Older Age
por: Alidjinou, Enagnon Kazali, et al.
Publicado: (2022)

Facilitating access to the renal transplant waiting list does not increase the number of transplantations: comparative study of two French regions
por: Lefort, Mathilde, et al.
Publicado: (2016)

Spatial and Temporal Virus Load Dynamics of SARS-CoV-2: A Single-Center Cohort Study
por: Alidjinou, Enagnon Kazali, et al.
Publicado: (2021)

194. Combinatorial Polyfunctionality Analysis of Antigen-specific T-cell Subsets (COMPASS) as a Predictor for Clinically Significant CMV Infection in the Letermovir Era
por: Zamora, Danniel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fanf5tmmetul972hnu3n9q9rkr